Full Press Release Details
Butterfly Network Reports Third Quarter 2022
Record Revenue with Momentum in Both Health
Systems and Software
Burlington, MA., and New York, NY, November 3, 2022 -- Butterfly Network,
Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound, today announced
financial results for the quarter ended September 30, 2022, and provided a business update.
| Reported total revenue of $19.6 million for the third quarter ended September 30, 2022, representing a 34.2% increase from $14.6 million for the third quarter ended September 30, 2021 | ||
| Introduced Butterfly's "Cloud 2.0" software, a launch that included several new product features and a Proficiency Management Solution for our Blueprint platform, that makes it even easier to manage your workflows and analysis across an institution. We are now providing Blueprint at Yale New Haven Health and signed a new contract with Stanford that includes an expanded system footprint of our enterprise software and probes. | ||
| Kicked off a first-of-its-kind clinical study, with the John Muir Cardiovascular Institution Research department, to evaluate a novel tool developed by Butterfly to provide novice clinicians-and patients-with the ability to assess pulmonary congestion themselves. | ||
| Partnership with Abdul Latif Jameel Health (ALJ) continues to strengthen with our recent launch in India. Through our partners, Butterfly will be available to the approximately 1 million registered physicians in the country, and we will bring our technology to practitioners working in developed, underdeveloped and remote areas, accelerating access to imaging for those who need it most. | ||
| Partnership with Bill & Melinda Gates Foundation (announced in first quarter) to improve maternal and fetal health in Sub-Saharan Africa with Butterfly iQ+ is on track, as we officially deployed 500 Butterfly iQ+ devices to healthcare practitioners in Kenya, at an event at Kenyatta University, and another 500 probes will be deployed to South Africa early next year. |
| Continued momentum in veterinary markets as Purdue University College of Veterinary Medicine announced Butterfly iQ+ Vet integration into the first year of the Doctor of Veterinary Medicine and Veterinary Nursing program. | ||
| Tightly managed our expenses and effectuated a planned workforce reduction in the quarter, informed by the better understanding of our strategic investment priorities, leading to lower operating expenses and extended cash runway. |
"This past quarter has been an important one for our learning and trajectory as a young and agile company that is on a mission
to enable more informed clinical decisions through access to valuable clinical insights using innovative ultrasound technology, made
simple with artificial intelligence - so that all people everywhere, get the right care, driven by the right clinical decisions
at the right time," said Dr. Todd Fruchterman, Butterfly's President and Chief Executive Officer. "With Butterfly,
providers now have the ability to use ultrasound to guide their assessment instead of doing an ultrasound to confirm their decision which
will lead to a major shift in how medicine is practiced, and care is delivered across all settings." Fruchterman continued "This
shift will take time because we are leading people through behavior change but the signals we are receiving and the conversations we
are having in the market reassert that Butterfly has the ability to fundamentally change the care-delivery experience for providers and
patients alike. We believe as strongly today as we ever have that Butterfly has the power to be as ubiquitous as the stethoscope,
in its utility in patient assessment, across all specialties, species and care settings. Our path to transformation at scale is on the
right track and while our rate of revenue growth was slower than we anticipated, we are receptive to the learnings in the market and
adapting where needed. We are also evolving as a company to bring discipline to both how we generate revenue and manage expense."
Looking at our 2022 guidance. Interest in Butterfly is strong and
the long-term opportunity and available market for our products is clear. As many in our industry have noted, intensified labor constraints
in the third quarter and associated budget pressures from temporary labor costs have limited client-side implementation capabilities
and caused deferrals in adoption of medical technology more broadly. As we do not have a good faith basis to assume this will immediately
reverse in the fourth quarter, along with our change in sales leadership, we believe it is prudent to revise our full year guidance to
$73-$76 million. However, due to the actions taken in Q3 and additional control measures we are able to reiterate our adjusted EBITDA
guidance in the range of a loss of $155-$145 million.
Third Quarter 2022 Financial Results
Third quarter total revenue increased 34.2% to $19.6 million from
$14.6 million in the third quarter of 2021. Product revenue increased 21.3% to $13.2 million from $10.8 million in the third quarter
of 2021. Software and other services revenue increased 71.1% to $6.5 million from $3.8 million in the third quarter of 2021.
Gross profit for the third quarter of 2022 was $11.0 million, compared
to gross profit of negative ($5.1) million in the third quarter of 2021. Adjusted gross profit was $12.0 million for the third quarter
of 2022, compared to an adjusted gross profit of $7.2 million in the third quarter of 2021.
Total gross margin for the quarter was 56.0%, compared to (35.0) %
in the third quarter of 2021. Adjusted gross margin was 61.2%, compared to 49.3% in the third quarter of 2021.
Total operating expenses for the quarter were $57.0 million, compared
to $51.9 million in the third quarter of 2021, representing an increase of 9.9% primarily due to higher payroll expenses and incremental
investment in our research & development and business infrastructure compared to the third quarter of 2022.
Net loss for the third quarter of 2022 was $54.7 million, compared
to a net loss of $13.6 million during the third quarter of 2021. Adjusted EBITDA was a loss of $32.9 million during the third quarter
of 2022, compared to a loss of $33.5 million in the third quarter of 2021.
Cash, cash equivalents and marketable securities including restricted
cash were $273 million as of September 30, 2022.
A reconciliation of Adjusted EBITDA to net loss, Adjusted gross profit
to gross profit, and Adjusted gross margin to gross margin for the three months ended September 30, 2022 and 2021, is provided in the
financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under
the heading "Non-GAAP Financial Measures."
A conference call to review the third quarter 2022 financial results
and provide a business update is scheduled for November 3, 2022, at 8:30 am Eastern Time. Interested parties may access the conference
call by dialing +1(844) 200-6205 (U.S.) or +1 (929) 526-1599 (Outside U.S.) and referencing Access Code: 741669. Additionally, a link
to a live webcast of the call will be available in the Investors section of Butterfly's website.
About Butterfly Network, Inc.
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York
Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe
whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging
and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible,
and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary
Ultrasound-on-Chip technology, Butterfly is paving the way for earlier detection and remote management of health conditions around
the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium,
Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland,
and the United Kingdom.
Butterfly iQ+ is a prescription device intended for trained healthcare
Non-GAAP Financial Measures
In addition to providing financial measurements based on generally
accepted accounting principles in the United States of America ("GAAP"), the Company provides additional financial metrics
that are not prepared in accordance with GAAP ("non-GAAP"). The non-GAAP financial measures included in this press release
are Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin. The Company presents non-GAAP financial measures in order to assist
readers of its condensed consolidated financial statements in understanding the core operating results that its management uses to evaluate
the business and for financial planning purposes. The Company's non-GAAP financial measures, Adjusted EBITDA, Adjusted gross profit
and Adjusted gross margin, provide an additional tool for investors to use in comparing our financial performance over multiple periods.
Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin are
key performance measures that the Company's management uses to assess our operating performance. These non-GAAP measures facilitate
internal comparisons of the Company's operating performance on a more consistent basis. The Company uses these performance measures
for business planning purposes and forecasting. The Company believes that Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin
enhance an investor's understanding of the Company's financial performance as they are useful in assessing its operating
performance from period-to-period by excluding certain items that the Company believes are not representative of its core business.
Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin
may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same
manner. Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin are not prepared in accordance with GAAP and should not be
considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company's
performance, you should consider Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin alongside other financial
performance measures prepared in accordance with GAAP, including net loss, gross profit, and gross margin.
The non-GAAP financial measures do not replace the presentation of
the Company's GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company's financial
results presented in accordance with GAAP. In this press release, the Company has provided a reconciliation of Adjusted EBITDA to net
loss, Adjusted gross profit to gross profit, and Adjusted gross margin to gross margin, the most directly comparable GAAP financial measures.
A reconciliation of Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin to corresponding GAAP measures is not available
on a forward-looking basis because the Company is unable to predict with reasonable certainty the non-cash component of employee compensation
expense, changes in its working capital needs, variances in its supply chain, the impact of earnings or charges resulting from matters
the Company considers not to be reflective, on a recurring basis, of its ongoing operations, and other such items without unreasonable
effort. These items are uncertain, depend on various factors, and could be material to the Company's results computed in accordance
with GAAP. Management strongly encourages investors to review the Company's financial statements and publicly filed reports in
their entirety and not rely on any single financial measure.
Forward Looking Statements
This press release includes "forward-looking
statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation
Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and,
consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as
"expect," "estimate," "project," "budget," "forecast,"